Review Article
The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
Table 2
Comparing main meta-analysis in terms of overall survival and morbidity.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HR: hazard ratio; RR: risk ratio; OR: odds ratio; MMC: mitomycin C; 5-FU: 5-fluorouracil; HIPEC: hyperthermic intraperitoneal chemotherapy; EPIC: early postoperative intraperitoneal chemotherapy; PIC: perioperative intraperitoneal chemotherapy; NIC: NIIC: normothermic intraoperative intraperitoneal chemotherapy; RCS: retrospective case series; PCS: prospective case series; N/A: not available; PC: peritoneal carcinomatosis. 1,2,3HIPEC, HIPEC + EPIC, and NIIC, respectively. No differences in morbidity between HIPEC and NIIC groups and the respective control arms. #Morbidity of anastomotic leak, bowel fistula, pancreatic fistula, intra-abdominal abscess, and neutropenia, respectively. *Data calculated with risk ratio (RR) and divided in two subgroups for analysis: mitomycin C subgroup RR = 0.75, 5-Fluorouracil RR = 0.69 versus control group RR = 0.45. £Morbidity of bone marrow suppression, anastomotic leak, bowel fistula, adhesive ileus, and liver disfunction, respectively. $Morbidity of anastomotic leak, ileus, bowel perforation, pancreatic fistula, marrow depression, fever, and intra-abdominal abscess, respectively. |